All In Biotech

Drug Trial Radar · NCT04314531

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 296 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

296

Actual

Start

Jul 1, 2020

Primary completion

Jun 4, 2025

Study completion Apr 2026

Sponsor

Sponsor type
Industry
First posted
Mar 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .

Conditions

  • Active Psoriatic Arthritis

Interventions

  • TILDDrug

    one 1 mL injection of study medication

  • matching placebo injectionsDrug

    one 1 mL injection of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects who achieve American College of Rheumatology [ACR20]Time frame: at Week 24

Locations

49 sites in 9 countries. Site status is shown where the registry gives one.

  • Sunpharma site no. 12

    Covina, California

  • Sunpharma site no. 04

    Miami Beach, Florida

  • Sunpharma site no. 02

    New Port Richey, Florida

  • Sunpharma site no. 07

    Tamarac, Florida

  • Sunpharma site no. 05

    Springfield, Missouri

  • Sunpharma site no. 10

    Lincoln, Nebraska

  • Sunpharma site no. 11

    Greenville, South Carolina

  • Sunpharma site no. 09

    Lubbock, Texas

  • Sunpharma site no. 03

    San Antonio, Texas

  • Sunpharma site no. 01

    Tomball, Texas

  • Sunpharma site no. 06

    Spokane, Washington

  • Sunpharma Site 39

    Phillip, Australian Capital Territory, Australia

  • Sunpharma site no. 08

    Hobart, Tasmania, Australia

  • Sunpharma Site 64

    Brno, Czechia

  • Sunpharma Site 97

    Prague, Czechia

  • Sunpharma Site 63

    Zlín, Czechia

  • Sunpharma Site 73

    Berlin, Germany

  • Sunpharma Site 92

    Herne, Germany

  • Sunpharma Site 113

    Kochi, India

  • Sunpharma Site 111

    Surat, Gujarat, India

  • Sunpharma Site 110

    Bangalore, Karnataka, India

  • Sunpharma Site 107

    Belagavi, Karnataka, India

  • Sunpharma Site 109

    Hubli, Karnataka, India

  • Sunpharma Site 108

    Pune, Maharashtra, India

  • Sunpharma Site 112

    Hyderabad, Telangana, India

  • Sunpharma Site 106

    Lucknow, Uttar Pradesh, India

  • Sunpharma Site 22

    Kitakyushu-shi, Japan

  • Sunpharma Site 88

    Kumamoto, Japan

  • Sunpharma Site 87

    Osaka, Japan

  • Sunpharma Site 23

    Tsu, Japan

  • Sunpharma Site 84

    Nagoya, Aichi-ken, Japan

  • Sunpharma Site 89

    Kitakyushu, Fukuoka, Japan

  • Sunpharma Site 86

    Sendai, Miyagi, Japan

  • Sunpharma Site 24

    Miyazaki, Miyazaki, Japan

  • Sunpharma Site 91

    Mitaka, Tokyo, Japan

  • Sunpharma Site 85

    Shinjuku, Tokyo, Japan

  • Sunpharma Site 90

    tabashi City, Tokyo, Japan

  • Sunpharma Site 93

    Bialystok, Poland

  • Sunpharma Site 95

    Bialystok, Poland

  • Sunpharma Site 94

    Lublin, Poland

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.